# Leflunomide in Previously Treated Metastatic Triple Negative Cancers

> **NCT03709446** · PHASE1,PHASE2 · COMPLETED · sponsor: **Joseph Sparano** · enrollment: 17 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Diseases
- Metastatic Triple Negative Breast Cancer

## Interventions

- **DRUG:** Leflunomide

## Key facts

- **NCT ID:** NCT03709446
- **Lead sponsor:** Joseph Sparano
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2025-11-27
- **Final completion:** 2025-11-27
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709446, "Leflunomide in Previously Treated Metastatic Triple Negative Cancers". Retrieved via AI Analytics 2026-05-16 from https://api.ai-analytics.org/clinical/NCT03709446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*